8-K: Premier Inc. Issues Supplemental Merger Disclosures Amid Lawsuits

Premier Inc. provides additional disclosures for its $28.25 per share acquisition by Patient Square Capital, addressing shareholder litigation.

Summary

• Premier, Inc. is being acquired by Premium Parent, LLC, an indirect subsidiary of funds managed by Patient Square Capital, LP, for $28.25 in cash per share of Class A common stock.
• The company filed this 8-K to provide supplemental disclosures to its Definitive Proxy Statement, which was previously filed on October 22, 2025.
• Three shareholder complaints and several demand letters have been filed, alleging the Definitive Proxy Statement is misleading and omits material information regarding the sales process, financial projections, and financial analyses.
• The complaints seek to enjoin the merger, or seek rescission/rescissory damages if consummated, along with costs and fees.
• Premier believes the claims are without merit and that supplemental disclosures are not legally required, but is providing them to avoid merger delays and minimize litigation costs and uncertainties.
• Supplemental disclosures include details on a confidentiality agreement with Patient Square Capital, which contained a customary standstill provision.
• Updated financial forecasts for fiscal years 2026 through 2039 are provided, showing Total Revenue growing from $955 million in FY2026 to $1,603 million in FY2039, and Unlevered FCF from $111 million in FY2026 to $229 million in FY2039.
• Goldman Sachs' discounted cash flow analysis yielded an illustrative present value per share range of $27.59 to $36.58, using discount rates of 8.5% to 10.5% and perpetuity growth rates of 1.0% to 2.0%.
• Goldman Sachs' present value of future stock price analysis resulted in an implied present value range of $22.18 to $30.86 per share.
• BofA Securities' analysis of selected publicly traded companies showed EV/CY 2025E Adj. EBITDA multiples ranging from 6.1x to 13.9x (mean 10.4x) and EV/CY 2026E Adj. EBITDA multiples from 5.7x to 12.7x (mean 9.5x).
• BofA Securities' review of Wall Street analyst price targets indicated a present value of $18.15 to $25.41 per share when discounted by one year at a 10.2% cost of equity.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the agreed-upon merger at a premium to recent analyst targets, offering a clear cash exit for shareholders. However, the ongoing shareholder litigation introduces uncertainty and potential delays, which slightly tempers the overall positive outlook.

Positives

• The acquisition price of $28.25 per share offers a clear cash exit for shareholders.
• The acquisition price falls within Goldman Sachs' illustrative discounted cash flow analysis range of $27.59 to $36.58 per share.
• The acquisition price is above the range of Wall Street analysts' discounted price targets, which were $18.15 to $25.41 per share.
• The company is proactively providing supplemental disclosures to mitigate risks and avoid delays associated with shareholder litigation, even while denying the merit of the claims.

Negatives

• Three shareholder complaints and multiple demand letters have been filed, alleging the Definitive Proxy Statement is misleading and omits material information.
• The litigation seeks to enjoin the merger or obtain rescissory damages, introducing uncertainty and potential delays.
• The company is incurring costs, risks, and uncertainties inherent in litigation, despite believing the claims are without merit.

Risks

• Inability to consummate the merger within the anticipated time period, or at all, due to failure to obtain required regulatory approvals, stockholder approval, or complete financing arrangements.
• Adverse effects on the market price of Premier's Class A Common Stock due to merger-related announcements.
• Disruption from the merger making it more difficult to maintain business and operational relationships, including retaining and hiring key personnel and maintaining relationships with customers, vendors, and others.
• The occurrence of any event, change, or other circumstances that could lead to the termination of the merger agreement.
• Risks related to disruption of current plans and operations or diversion of management's attention from ongoing business due to the merger.
• Significant transaction costs associated with the merger.
• Risk of litigation and/or regulatory actions related to the merger or unfavorable results from currently pending or future litigation and proceedings.

Future Outlook

The filing primarily focuses on the ongoing merger process and related litigation, providing supplemental financial forecasts for valuation purposes extending to fiscal year 2039. The ultimate future outlook for Premier, Inc. is its acquisition by Patient Square Capital, LP, after which it will become a wholly owned subsidiary.

Management Comments

• The Company believes that the claims asserted in the Matters are without merit and supplemental disclosures are not required or necessary under applicable laws.
• In order to avoid the risk that the Matters delay or otherwise adversely affect the merger, and to minimize the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, the Company is supplementing the Definitive Proxy Statement.
• Nothing in this Current Report on Form 8-K shall be deemed an admission of the legal merit, necessity or materiality under applicable laws of any of the disclosures set forth herein. To the contrary, the Company specifically denies all allegations in the Matters that any additional disclosure was or is required or material.

Industry Context

The filing provides industry context through BofA Securities' analysis of selected publicly traded companies in the healthcare supply chain services and performance services industries, including McKesson Corporation, Cencora, Inc., Cardinal Health, Inc., IQVIA Holdings Inc., and R1 RCM, Inc. It also references selected precedent transactions in these industries, such as Patient Square Capital's acquisition of Patterson Companies, Inc. and TowerBrook Capital Partners' acquisition of R1 RCM, Inc., to benchmark valuation multiples.

Comparison to Industry Standards

• Premier's EV/CY 2025E Adj. EBITDA multiple (8.5x based on Management Projections, 8.8x based on Wall Street research) was lower than the mean (10.4x) and median (11.1x) of selected publicly traded companies in the healthcare supply chain and performance services industries.
• Premier's EV/CY 2026E Adj. EBITDA multiple (8.7x based on Management Projections, 9.0x based on Wall Street research) was lower than the mean (9.5x) and median (10.2x) of selected publicly traded companies.
• The overall low to high EV to NTM Adj. EBITDA multiples observed for target companies in selected precedent transactions ranged from 7.8x to 13.2x, with a mean of 11.2x and a median of 11.6x, providing a benchmark for the merger's valuation.

Corporate Governance

Legal Proceedings

• Clark v. Premier, Inc. et al., Index No. 659448/2025 (N.Y. Sup. Ct., County of New York Oct. 29, 2025).
• Johnson v. Premier, Inc. et al., Index No. 659436/2025 (N.Y. Sup. Ct., County of New York Oct. 29, 2025).
• Garfield v. Premier, Inc. et al., Index No. 629800/2025 (N.Y. Sup. Ct., County of Suffolk Nov. 3, 2025).
• Multiple demand letters from purported stockholders alleging similar deficiencies in the Preliminary and/or Definitive Proxy Statements.

Related Party Transactions

• Funds managed by affiliates of Goldman Sachs (financial advisor to Premier) that are almost entirely for the benefit of third-party clients are invested in funds managed by affiliates of Patient Square Capital (the acquirer). However, funds managed by affiliates of Goldman Sachs were not co-invested with Patient Square Capital and/or its affiliates as of September 21, 2025.

Stakeholder Impact

• Shareholders: Will receive $28.25 in cash per share upon consummation of the merger, representing a premium over recent market prices and analyst targets.
• Company: Faces potential delays and costs due to ongoing litigation, requiring management attention and resources to address legal challenges.
• Employees, Customers, Vendors: Risk of disruption from the merger making it more difficult to maintain business and operational relationships, including retaining and hiring key personnel and maintaining relationships with these stakeholders.

Next Steps

• Consummation of the merger with Premium Parent, LLC, subject to regulatory approvals and stockholder approval.
• Resolution of the pending shareholder litigation and any future complaints or demand letters related to the merger.

Key Dates

Recommendation

The filing details supplemental disclosures related to an agreed-upon merger where shareholders are set to receive $28.25 per share. While litigation exists, the company is taking steps to mitigate delays. For existing shareholders, holding until the merger's completion to receive the cash consideration is the most logical action, assuming the merger proceeds as planned. There is no immediate 'buy' opportunity as the price is fixed, and 'sell' would forgo the agreed-upon cash consideration.

Keywords

Premier Inc., Merger, Acquisition, Patient Square Capital, 8-K, Proxy Statement, Shareholder Litigation, Financial Forecasts, Healthcare Supply Chain, Performance Services, Corporate Governance, Discounted Cash Flow, EBITDA, Unlevered Free Cash Flow